Four-year longitudinal multicenter susceptibility trends of aztreonam–avibactam and ceftazidime–avibactam and dose optimization in critically ill patient populations against carbapenem-resistant Enterobacterales bloodstream infections

Engineering Microbiology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles